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RGD (Ad) is currently under investigation in clinical trials
for glioblastoma, including in combination with temozolomide
(TMZ), the standard chemotherapy for this tumor. Previously,
we showed that the efﬁcacy of Delta24-RGD in a murine model
is primarily dependent on the virus-induced anti-tumor im-
mune response. As observed with most chemotherapies, TMZ
has pronounced immune-modulating effects. Here, we studied
the combined effects of these treatments in a murine glioma
model. In vitro, we observed a synergistic activity between
Delta24-RGD and TMZ. In vivo, C57BL/6 mice bearing intra-
cranial GL261 tumors were treated with TMZ for 5 days either
prior to intratumoral Delta24-RGD injection (TMZ/Ad) or
post virus injection (Ad/TMZ). Notably, the Ad/TMZ regimen
led to similar tumoral CD8+ T cell inﬂux as the virus-only treat-
ment, but increased the ability of CD8+ T cells to speciﬁcally
recognize the tumor cells. This was accompanied by improved
survival. The TMZ/Ad regimen also improved survival signiﬁ-
cantly compared to controls, but not compared to virus alone.
In this group, the inﬂux of dendritic cells is impaired, followed
by a signiﬁcantly lower number of tumor-inﬁltrating CD8+
T cells and no recognition of tumor cells. Depletion of either
CD4+ T cells or CD8+ T cells impaired the efﬁcacy of
Delta24-RGD, underscoring the role of these cells in therapeu-
tic activity of the virus. Overall, we show that the addition of
TMZ to Delta24-RGD treatment leads to a signiﬁcant increase
in survival and that the order of sequence of these treatments
affects the CD8+T cell anti-tumor activity.
INTRODUCTION
Glioblastoma (GBM) is both the most common and most malignant
of all brain tumors in adults.1 Despite current standard treatment by
surgical resection, radiation therapy, and chemotherapy, the prog-
nosis remains dismal.1 The median survival time of GBM patients
at the time of diagnosis is only 14.6 months,2 highlighting the neces-
sity of novel therapies. Delta24-RGD, an oncolytic adenovirus, has
shown promising preclinical efﬁcacy and is currently under investiga-Mol
This is an open access article under the CC BY-Ntion in clinical phase I/II trials in recurrent GBM patients.3 This virus
selectively replicates in tumor cells harboring a mutation in the reti-
noblastoma (Rb) tumor suppressor gene or pathway but not in
normal healthy cells.4 After replication, the produced viral particles
are released from the host cell by lysis and spread to neighboring
tumor cells.
Recently, a clinical trial combining the chemotherapeutic agent temo-
zolomide (TMZ) with Delta24-RGD was initiated.5 Previously, TMZ
was shown to synergize with Delta24-RGD in human U87MG glioma
cells by disabling the cellular DNA repair machinery and improving
the survival of mice bearing U87 xenografts.6 In an immune-compe-
tent mouse model, we have previously shown that the therapeutic
efﬁcacy of Delta24-RGD is primarily dependent on an anti-tumor
immune response, most likely executed by CD4+ or CD8+ T cells.7,8
On the one hand, TMZ induces lymphopenia,9 which has been re-
ported to be particularly pronounced with respect to CD4+ cells,
CD8+ T cells, and natural killer (NK) cells.10 On the other hand, there
are also reports that demonstrate that immune suppression is lowered
by TMZ by decreasing the numbers of peripheral regulatory T cells
(Tregs),11 which could be favorable in the combined treatment
setting. Also, it has been postulated that TMZ increases tumor
antigen presentation to immune cells by inducing autophagic tumor
cell death rather than apoptosis or necrosis, therewith facilitating the
involvement of antigen-presenting cells, such as dendritic cells (DCs),
and improved generation and localization of anti-tumor CD8+
T cells.12–14 We hypothesized that these differential effects of TMZ
depend on the timing of chemotherapy in relation to oncolytic virus
treatment, which would be in line with observations from immuno-
therapy studies using adenoviral vectors and/or immune-stimulatoryecular Therapy: Oncolytics Vol. 5 June 2017 ª 2017 The Authors. 11
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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BA Figure 1. Synergy between TMZ and Delta24-RGD
(A) Viability of TMZ- (white bars), Delta24-RGD- (gray
bars), and combination- (black bars) treated GL261
cells in triplicate was measured after 5 days. Dosages
were chosen around the predetermined IC50. Viability,
determined by the presence of ATP, is expressed as a
percentage of non-treated cells. Error bars indicate SD;
*p < 0.05. (B) Using the Chou-Talalay formulas, com-
bination index (CI) was calculated. A CI <1 indicates
synergy.
Molecular Therapy: Oncolyticscytokines.15,16 To test this hypothesis, we studied the effects of the
combination and sequence of TMZ and Delta24-RGD treatment on
immune response and therapeutic outcome in an immune-competent
mouse model for glioma.
RESULTS
TMZ and Delta24-RGD Act Synergistically In Vitro
To evaluate the cytotoxicity and interaction of TMZ and Delta24-
RGD (Ad) on murine glioma GL261 cells, synergy between the two
treatment modalities was assessed in vitro by the Chou-Talalay
method.17 Three-fold serial dilutions of Ad and TMZ, with several
concentration points above and below the half maximal inhibitory
concentration (IC50) for these agents, were added simultaneously to
GL261 cells, and cell viability was measured after 5 days (Figure 1A).
The combination reduced viability compared to the mono-treatments
(all p < 0.05), and the calculated combination index (CI) also showed
a synergistic effect (CI < 1) between the two treatments (Figure 1B).
Combined Delta24-RGD and TMZ Treatment Induces Apoptosis
and Autophagic Flux
Multiple types of induced cell death have been described for both
TMZ and Delta24-RGD, where autophagic cell death and apoptosis
are the most important mechanisms.12 To evaluate the effect of
combination therapy on these two types of cell death, a western
blot analysis for LC3-I/LC3-II and p62 expression was performed,
as conversion of LC3-I to LC3-II and consumption of p62 have
been suggested to provide indicators of autophagic activity. Apoptosis
was assessed by the caspase 3/7 assay.
Induction of the LC3-II protein was most profound in the TMZ-
treated cells and combination-treated cells (Figure 2A). When quan-
tiﬁed, a ratio >1 between LC3-II and LC3-I is considered indicative of
active autophagy.18 Whereas Delta24-RGD did not induce LC3 con-
version in GL261 cells, TMZ induced an almost 8-fold increase in the
LC3-II/LC3-I ratio by 72 hr (Figure 2B, line indicates 1). The combi-
nation treatment induced an intermediate response. p62 accumulated
in virus-treated cells and, in particular, in the combination-treated
cells up to 48 hr and decreased again by 72 hr (Figures 2C and 2D).
Analysis of caspase 3/7 activity in Delta24-RGD-, TMZ-, and combi-
nation-treated treated GL261 cells clearly revealed the induction of
apoptosis in the murine glioma cells after TMZ treatment (Figures
3A and 3C, p < 0.001). This activation is not hampered when the12 Molecular Therapy: Oncolytics Vol. 5 June 2017two treatments are combined (Figure 3A, non-treated [NT] versus
combination, p < 0.001). Interestingly, addition of the pan-caspase in-
hibitor Z-VAD-FMK to TMZ or combination-treated cells inhibited
the cleavage of caspase 3/7 (p < 0.001; Figure 3A). Pictures show com-
parable morphology of the cells in each of the different treatment
groups with or without Z-VAD-FMK (Figure 3B). Overall, our data
suggest that both autophagic cell death and apoptosis are induced
in GL261 cells by combining TMZ and Delta24-RGD treatment.
Combining TMZ and Delta24-RGD Improves Survival of Glioma-
Bearing Mice
To assess the effects of combined treatment on survival, GL261
tumor-bearing mice were treated with TMZ, Delta24-RGD, or a com-
bination schedule. As pre- (TMZ/Ad) or post- (Ad/TMZ) treatment
with TMZ could inﬂuence the therapeutic activity of the virus, both
treatment schedules were tested. Details of the experimental design
are depicted in Figure 4A. TMZ delayed tumor growth for approxi-
mately 4 days (green, p = 0.01, Figure 4B) and Delta24-RGD
improved survival compared to the NT mice, leading to long-term
survival (>120 days) in 14% of animals (orange, p = 0.0281). The
two combination regimens (blue [Ad/TMZ] and red [TMZ/Ad])
extended median survival compared to the NT mice (both p <
0.0001, with 21 and 13 days, respectively). Furthermore, the Ad/
TMZ regimen (blue) improved survival signiﬁcantly compared to
both TMZ and Delta24-RGD alone (p < 0.0001 and p = 0.0353,
respectively), whereas the TMZ/Ad regimen (red) improved survival
signiﬁcantly compared to TMZ (p = 0.0045), but not to Delta24RGD
(p = 0.1043).
The intratumoral viral load of the different treatment groups was as-
sessed over time by quantifying the viral E1A DNA content in the tu-
mor-bearing hemispheres. At 3 and 8 days post virus injection, the
number of E1A copies was similar in the three treatment groups,
although the overall E1A copy numbers on day 8 were lower than
on day 3 (Figure 4C).
TMZ Prior to Delta24-RGD Treatment Abrogates Intratumoral
Accumulation of CD8+ T Cells
We previously showed that Delta24-RGD elicits an anti-tumor im-
mune response, which is, at least in part, responsible for the therapeutic
effect of the virus.7,8 To assess whether CD4+ or CD8+ T cells are the
effector cells in this response, anti-CD4 and anti-CD8 antibodies
were used to deplete these cells in virus-treated mice. Delta24-RGD
A B
C D
Figure 2. Combined Treatment Induces Autophagy
(A and B) The ratio between LC3-II and LC3-I was determined by western blotting (A) and quantified using Image Lab 4.1 software (Biorad) (B). A ratio between LC3-II and
LC3-I >1 indicates active autophagy, as shown by the rapamycin-treated positive control (striped bar) at 24 hr. TMZ- (light gray bars) treated cells show a high ratio after 72 hr,
while Delta24-RGD (dark gray bars) does not induce autophagy. Non-treated (NT) cells were used as a control (white bars). In the combination-treated cells (black bars),
autophagy is induced at 72 hr, albeit at a lower level compared to TMZ. (C and D) The accumulation of p62 was also determined by western blotting as a measure of
autophagy (C) and the intensity was corrected by the intensity levels of actin (D).
www.moleculartherapy.orgtreatment led to 35% long-term survivors (p < 0.05 NT versus Ad),
while concomitant depletion of CD4+ or CD8+ cells completely abol-
ished the therapeutic effect of the virus (Figure 5, p = 0.0066 and p =
0.0265, respectively), highlighting the importance of both subtypes of
T-lymphocytes for the efﬁcacy of Delta24-RGD treatment.
To examine whether co-treatment with TMZ affects this response, we
mapped the local immune environment during TMZ, Delta24-RGD,
and the combination treatments. Brains were harvested at 3 and
8 days post-treatment to analyze brain-inﬁltrating leukocytes by
ﬂow cytometry (Figure 6). An increase in inﬁltrating macrophages
(CD3F4/80+) in the tumor-bearing hemisphere between day 3 and
day 8 was found in all conditions, including the PBS-treated control
mice. On day 3, these numbers were slightly higher in the mice treated
with Delta24-RGD or combination therapy compared to PBS or TMZ
monotherapy; however, these differences did not reach statistical sig-
niﬁcance (Figure 6A, left graph). The relative numbers of NK cells
(CD3 NK1.1+; Figure 6A, middle graph) and DCs (CD45+ CD11c+
MHCII+, right graph) were lower compared to macrophages. Percent-
ages of NK cells and DCs were markedly increased at day 3 post-treat-
ment in the virus (Ad) group and the post-treatment (Ad/TMZ) group,
whereas the pre-treatment (TMZ/Ad) group revealed virtually no NK
cell orDC inﬁltration at this time point. At day 8, NK cell andDC levels
were normalized to the levels in control mice in all treatment groups.
A signiﬁcant increase in CD4+ T cells (CD3+ CD4+) was detected
8 days post-treatment in the TMZ, Ad, and Ad/TMZ groups (Fig-ure 6B, left graph, p < 0.05), but not in the TMZ/Ad group. The num-
ber of Tregs (CD4+ CD25+FoxP3+) was generally low; however,
increased numbers were present after 8 days in the Ad and Ad/
TMZ post-treatment groups (middle graph, p < 0.05). The most pro-
nounced effect of the different treatment schedules was found in the
CD8+ T cell population (CD3+ CD8+; Figure 6B, right graph). These
numbers increased to approximately 10-fold on day 8 in the Ad and
Ad/TMZ groups, whereas numbers remained near baseline in the
TMZ/Ad group (p < 0.05). Therefore, it appears that pre-treatment
of mice with TMZ reduces the virus-induced early inﬂux of DCs
and NK cells and the subsequent inﬂux of CD4+ and, in particular,
CD8+ T cells.
Ad/TMZ, but Not TMZ/Ad, Regimen Results in Enhanced
Recognition of Glioma Cells by CD8+ T Cells
Whether the sequence of TMZ and Delta24-RGD treatment affects
the speciﬁc anti-tumor response was evaluated in splenocytes derived
8 days post virus injection (Figure 7). Splenocytes from Delta24-
RGD-treated mice produced more interferon g (IFN-g) compared
to splenocytes from NT mice when cocultured with GL261 cells
(NT versus Ad, white bars, p = 0.0059). Strikingly, splenocytes
from the post-treatment regimen (Ad/TMZ) produced 6-fold more
IFN-g than Ad-only treated mice (NT versus Ad/TMZ p < 0.0001,
Ad versus Ad/TMZ p < 0.0001). In contrast, splenocytes from
TMZ/Ad-treated mice did not recognize GL261 cells, further sup-
porting the view that TMZ pre-treatment abrogates virus-induced
immune response to the tumor.Molecular Therapy: Oncolytics Vol. 5 June 2017 13
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Figure 3. Combined Treatment Induces Caspase 3/7
(A and B) The induction of caspase 3/7, as a measure of apoptosis (A) (error bars indicate SD), was quantified by counting the GFP-positive cells in triplicate (B), which
represent cells with active caspase 3/7. After 72 hr, significantly more caspase 3/7-positive cells are detected in the TMZ and combined treated cells (p < 0.05). Z-VAD-FMK,
a pan-caspase inhibitor, blocked the induction of caspase 3/7 in TMZ and combined treated cells (p < 0.05).
Molecular Therapy: OncolyticsDISCUSSION
For further clinical development of the oncolytic adenovirus Delta24-
RGD for glioma, evaluation of combination treatment with current
standard therapies is warranted. It was previously shown in a glioma
xenograft model that TMZ acts synergistically with the virus and that
this effect is mainly based on virus-mediated interference with DNA
repair genes: in particular, MGMT.6 However, more recent data point
toward a major contribution of the immune system in Delta24-RGD
therapy, and combined therapy with immune suppressive agents,
such as TMZ, may undermine this response.7,8 On the other hand,
TMZ may also enhance the anti-tumor response (e.g., by decreasing
peripheral Tregs or increasing tumor-antigen presentation).11,12 To
gain insight into these interactions, we assessed the effects of the com-
bination of Delta24-RGD with TMZ given either prior to injection or
post virus injection in an immune-competent mouse model.
Combining TMZ with Delta24-RGD signiﬁcantly improved the sur-
vival of glioma-bearing mice compared to controls in both combina-
tion groups, yielding 30%–50% long-term survivors (Figure 4). Only
the Ad/TMZ combination regimen improved survival signiﬁcantly
compared to both mono-treatment groups. Analysis of the intracra-
nial tumors of the virus-treated mice revealed similar amounts of
virus in the combination groups versus Delta24-RGD-treated mice,14 Molecular Therapy: Oncolytics Vol. 5 June 2017suggesting that improved efﬁcacy was not due to enhanced intratu-
moral virus replication. It cannot be excluded, however, that retrieved
viral amounts were affected by differences in tumor size at the time of
virus injection as a result of the timing of TMZ therapy. Moreover, we
have previously shown that the Delta24-RGD lytic cycle is attenuated
in murine cells, which corresponds with decreasing viral amounts
between days 3 and 8 in all three groups.7
To gain insight into the mechanisms underlying the in vivo synergis-
tic activity of Delta24-RGD and TMZ, several experiments were per-
formed. Synergy between the two treatment modalities with respect
to oncolysis was demonstrated in vitro by Chou-Talalay analysis17
(Figure 1). One explanation for the synergy is that Delta24-RGD
silences theMGMT promoter and/or interacts with other DNA repair
genes,6 thereby enhancing TMZ efﬁcacy. Indeed, GL261 tumors have
been reported to weakly express MGMT19 in vivo, although we could
not conﬁrm this in vitro (not shown). We cannot exclude, however,
that other DNA repair enzymes are affected by Delta24-RGD
infection.
Both autophagy and apoptosis are reported to play a role in Delta24-
RGD- and TMZ-induced cell death.20,21 Surprisingly, we found that
autophagy, as measured by the conversion of the protein LC3-I to
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Figure 4. The Combination of TMZ and Delta24-RGD Significantly Improves Survival of Glioma-Bearing Mice
(A) Schematic drawing of treatment schedules. At day 0, GL261 tumor cells were injected (tumor inoculation [TI]), and, after 5 days, treatment was initiated according to
schedule. Mice were followed for survival or sacrificed (y) at earlier indicated time points. (B) Results of two combined survival studies with control non-treated mice (NT, gray
line, n = 12), TMZ-treatedmice (green, n = 11), Delta24-RGD-treatedmice (orange, n = 7), post-treatment schedule (Ad/TMZ, blue, n = 13) and pre-treatment schedule (TMZ/
Ad), red, n = 13). All treatment groups significantly prolong survival compared to the controls (log rank test, *p < 0.05). The Ad/TMZ group is also significantly different from
TMZ alone or Delta24-RGD alone (p < 0.0001 and p = 0.0353, respectively). (C) To determine tumoral viral titers, E1A copies were measured by PCR in brain lysate 3 days
(white bars) and 8 days (black bars) post injection (pi). There is no significant difference between the treatment groups (p > 0.05). Error bars indicate SD.
www.moleculartherapy.orgLC3-II, is not induced above control levels by Delta24-RGD in GL261
cells (Figure 2). Addition of TMZ to the viral treatment did increase
the ratio of LC3-II/LC3-I, but not to the extent induced by TMZ
monotherapy. Interestingly, whereas a decrease in p62 is expected dur-
ing autophagy, we observed accumulation of p62 after virus treatment,
whichwas further enhanced in combinationwith TMZ. Thismay sug-
gest that the increased autophagicﬂux,which is noted by the LC3 turn-
over, is hampered in the degradation phase. Others have reported
Delta24-RGD to preferentially induce autophagy over cell lysis in tu-
mor cells during the ﬁnal stages of the replication cycle.8,21 This
discrepancy with our results may possibly be explained by species-
related differences in response to the virus and the attenuated
replication cycle of Delta24-RGD in the murine GL261 cells may
be associated with a different mechanism of cell death induction.7
Apoptosis, as measured by caspase 3/7 activation, is also induced in
TMZ-treated cells over a 3-day period, while Ad alone does not in-
crease apoptosis. The combination treatment also results in high levels
of apoptosis. Caspase cleavage, however, does not always lead to
apoptotic cell death.22 Indeed, the pan-caspase inhibitor Z-VAD-
FMK reduced expression of caspase 3/7 (Figure 3) without inducing
cytotoxicity (results not shown). Autophagy, initially perceived as a
cell survival mechanism, is associated with immunogenic cell death,
whereas apoptosis generally is not. The two cell death-associated
mechanisms are, however, not mutually exclusive.23 Furthermore,
pathogen-induced cell death is, by deﬁnition, an immunogenic form
of cell death, as is shown by the release ofHMGB1 after other oncolytic
adenovirus infections.12,24,25 Overall, we observed that TMZ effec-
tively induces autophagic ﬂux and apoptosis and that the combination
of both treatments ensures that both processes are activated in the in-
fected cells. It cannot be excluded that other forms of cell death (e.g.,
necrosis, anoikis, and non-apoptotic programmed cell death), which
were not investigated in this study, may also contribute to the syner-
gistic cell killing by Delta24-RGD and TMZ.26
In addition to the cell-killing properties of the two treatments, the
interaction with the immune system also is anticipated to affect thetherapeutic outcome. We previously demonstrated that Delta24-
RGD activity in this model is primarily driven by an anti-tumor
response.7,8 Here we show, in a depletion experiment, that both
CD4+ T cells and CD8+ T cells are required for this anti-tumor
response (Figure 5). TMZ has been shown to change leukocyte pro-
portions by inducing a transient lymphopenia of CD4+ T cells and
NK cells and by increasing numbers of Tregs without affecting mono-
cytes.10 It is believed that the repopulating immune cells experience
less competition for antigens,27 resulting in increased numbers of
effector T cells speciﬁc for tumor and/or virus. Adding TMZ to
Delta24-RGD treatment may, therefore, enhance the anti-tumor im-
mune response. On the other hand, the TMZ-induced lymphopenia
could hamper the therapeutic efﬁcacy of the virus by suppressing
an anti-tumor immune reaction due to the increased numbers of
Tregs and insufﬁcient T effector cell activation and expansion. The
splenocyte assay revealed that T cells do recognize the tumor cells
in the post-treatment group, and, in fact, are even more pronounced
than in mice treated with Delta24-RGD only (Figure 7), which
suggests that they might have a higher frequency. Interestingly, this
reaction was not detected in mice from the pre-treatment group,
underscoring that the order in which TMZ and Delta24-RGD therapy
is administered is of paramount importance in the generation of vi-
rus-induced anti-tumor immunity. When interpreting these results,
the timing of TMZ administration and the analyzed time points in
relation to the number of days after viral treatment should be kept
in mind.
Differences in tumoral immune cell inﬂux between the two com-
bination regimens were also observed (Figure 6). In general, viral
treatment induces chemotaxis signaling, leading to the inﬂux of mac-
rophages, NK cells, DCs, and CD4+ and CD8+ T cells with a more
rapid inﬁltration of the tumor by macrophages than by CD8+
T cells.7 Strikingly, DC inﬁltration is completely abrogated in mice
receiving the TMZ/Ad pre-treatment schedule, but not in mice
receiving the Ad/TMZ post-treatment schedule. This is subsequently
reﬂected in a diminished inﬂux of CD4+ and, in particular, CD8+Molecular Therapy: Oncolytics Vol. 5 June 2017 15
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(A) Schematic drawing of treatment schedules. TI, tumor inoculation. (B) Survival analysis for control non-treated mice (n = 6, black line), Delta24-RGD-treated mice (n = 7,
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Molecular Therapy: OncolyticsT cells in TMZ/Ad-treated mice, which is an important ﬁnding
as CD8+ T cells are required for the therapeutic efﬁcacy of Delta24-
RGD (Figure 5). Together, the immune cell inﬂux data are congruent
with the results of the splenocyte assay, showing that the pre-treat-
ment (TMZ/Ad) schedule abrogates immune cell inﬂux and genera-
tion of a tumor-speciﬁc T cell response. The similar survival beneﬁt in
both combination treatment groups may be a consequence of two dif-
ferential mechanisms: the direct cytotoxic/oncolytic effects of TMZ
and Delta24-RGD versus an induced anti-tumor immune response.
The lack of immune cell inﬂux in the pre-treatment group may
have led to improved and prolonged oncolytic activity of the virus
in these mice because the virus is cleared less rapidly. Despite this,
and based on the immune cell inﬂux and splenocyte data, we recom-
mend the post-treatment sequence (Ad/TMZ) for further (clinical)
evaluation.
In conclusion, in an immune-competent setting, the oncolytic virus
Delta24-RGD administered prior to TMZ signiﬁcantly prolongs sur-
vival without hampering the anti-tumor immune response, thereby
highlighting the potency of this combination strategy over the use
of single agents.
MATERIALS AND METHODS
Cell Culture
Both the murine glioma cell line GL261, obtained fromNational Can-
cer Institute (NCI) Tumor Repository and the human lung carcinoma
cell line A549 (ATCC) were cultured in DMEM (Life Technologies)
supplemented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (both Life Technologies).
Viruses and Chemicals
The human Delta24-RGD virus was previously described by Suzuki
et al.28, and viral stocks were produced as described previously.29
For puriﬁcation, the AdEasy Virus Puriﬁcation Kit (Stratagene) was
used, and titration of the new virus batches was done on A549 cells
using the Adeno-X Rapid Titer Kit (Clontech Laboratories). TMZ
(kindly provided by Sun Pharmaceutical Industries) was dissolved
in DMSO (Sigma-Aldrich) for in vitro experiments and further16 Molecular Therapy: Oncolytics Vol. 5 June 2017diluted in cell culture medium. To control for DMSO-induced cyto-
toxicity, the highest percentage of DMSO was taken as a control. For
the in vivo study, TMZ was dissolved in PBS (Life Technologies).
In Vivo Experiments
All animal experiments described in this paper have been conducted
according to Dutch guidelines for animal experimentation. All animal
experiments were reviewed by and performed with approval of the
Erasmus MC Animal Ethics Committee (DEC, protocol numbers
EMC3045 and EMC3069) of the Erasmus Medical Center. The
mice were housed in individually ventilated cages with sterile
bedding, water, and rodent chow. Female C57BL/6 mice (6–9 weeks
old, Harlan) were stereotactically injected with 5  104 GL261 cells
3 mm deep in the right hemisphere (2.2 mm lateral, 0.5 mm anterior
of bregma) as described previously.30 Treatment for the combination
of Delta24-RGD with TMZ started after 5 days with the following
regimens: PBS as a control, TMZ alone (7.5 mg/kg/day, administered
intraperitoneally for 5 days), Delta24-RGD alone (8.7 108 IU/mice,
intratumorally), pre-treatment with TMZ followed by Delta24-RGD,
and Delta24-RGD followed by post-treatment with TMZ. For the
CD4 and CD8 depletion experiment, animals received 0.2 mg per
mouse anti-CD4 (Clone GK1.5, Bio X Cell) or 0.2 mg per mouse
anti-CD8 (Clone 53-6.72, Bio X Cell) on days 1, 2, and 3. On day 4,
depletion of CD4+ or CD8+ was conﬁrmed in the blood of all mice
using ﬂuorescence-activated cell sorting (FACS) analysis (results
not shown). At day 5, mice received Delta24-RGD (3.5  107 IU/
mice, intratumorally). Injection of anti-CD4 and anti-CD8 was
repeated every 7 days. Mice were followed for survival and sacriﬁced
uponmore than 20% weight loss or appearance of neurological symp-
toms. Results of two separate Delta24-RGD + TMZ combination ex-
periments were combined. For ﬂow cytometry analysis, qPCR, and
the splenocyte assay, mice of the combination study were sacriﬁced
at earlier time points (3 and 8 days after the start of the treatment
schedule), and brains and spleens were harvested.
Analysis of the In Vivo Viral Load by qPCR
To compare the in vivo viral load between the different treat-
ment schedules, ﬁve cryosections of 10 mM were cut from the
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Figure 6. Intratumoral Influx of CD8 T cells Is Enhanced in Ad/TMZ, but Not TMZ/Ad, Treatment
(A and B) Influxed intratumoral immune cells (n = 2 for mono-treatments, n = 3 for combined treatments), both from the innate (A) and adaptive (B) arm of the immune system,
were characterized and quantified using flow cytometry analysis 3 (white bars) and 8 (black bars) days post viral injection. Error bars indicate SD; *p < 0.05. (A) For the innate
arm, macrophages (% CD3 F4/80+ cells of total events, left graph), natural killer cells (NK) (CD3 NK1.1+, middle graph), and dendritic cells (DC) (CD45+ CD11c+ MHCII+,
right graph) were measured (B) For the adaptive arm, the amounts CD4+ T cells (CD3+ CD4+, left graph), regulatory T cells (Treg, CD4+ CD25+ FoxP3+, middle graph), and
CD8+ T cells (CD3+ CD8+, right graph) were assessed.
www.moleculartherapy.orgtumor-containing hemisphere near the injection site. A homogeneous
solution was made by crushing the tissue in RPMI medium (Life
Technologies) with a micro tissue homogenizer. Nucleic acids were
extracted using the MagNA Pure LC Total Nucleic Acid Isolation
Kit (Roche Molecular Systems). The DNA concentration of each
sample was measured using the Nanodrop machine (Thermo
Scientiﬁc) and was not signiﬁcantly different between the treatment
groups (results not shown). Ampliﬁcation was performed using
the 2x Taqman Universal Mastermix (Life Technologies), and
primers add24-RGDfwd (50-acactaaacggtacacaggaaacag-30) and
add24-RGDrev (50-gccagaccagtcccatgaaa-30) in the presence of
FAM-BHQ labeled probe add24-RGD (50-ccgcggagactgtttctgc
cca-30). Real time PCR ampliﬁcation was measured on a Lightcycler
480 (Roche Molecular Systems). In parallel, a calibration curve of
a Delta24-RGD stock with a known viral particle titer was run.
Chou-Talalay Assay
Drug synergy can be calculated by using the Chou-Talalay equa-
tions.17 GL261 cells were plated at 1,000 cells/well in a 96-well plate
(Greiner Bio One) and, after 24 hr, cells were treated in triplicate
with either TMZ or Delta24-RGD alone or in combination. Concen-
trations varied between 1/27*IC50 and 9*IC50, based on predeter-
mined IC50 values of 100 mM TMZ and MOI 170 Delta24-RGD.
On day 5, viability was determined using the Cell Titer Glo Assay
(Promega). Dose response curves were ﬁtted, and the CI was calcu-lated. A CI >1 is considered antagonistic, CI = 1 additive, while
synergy is indicated by CIs of <1.
Caspase 3/7 Assay
GL261 cells/well (8,000/well) were seeded in a clear-bottom black 96-
well plate (Greiner Bio One). The following day, cells were treated
with TMZ (100 mM), Delta24-RGD (100 MOI), or the combination
in triplicate. Untreated cells and DMSO- (0.1%) treated cells served
as negative controls. The CellPlayer Caspase 3/7 reagent (Essen
Bioscience) was added to the wells according to the manufacturer’s
instructions. The pan-caspase inhibitor Z-VAD-FMK (MBL Interna-
tional) was added at a concentration of 20 mM. Fluorescent signals
from caspase 3/7-positive cells were measured every 3 hr using
IncuCyte (Essen Bioscience). The object count (GFP-positive cells)
was determined using the IncuCyte Software (Essen Bioscience).
After 72 hr, cell viability was determined using the Cell Titer Glo
Assay (Promega).
LC3/p62 Western Blotting
T75 ﬂasks of GL261 cells were treated with 100 mM TMZ, 100 MOI
Delta24-RGD, or both and harvested 24 hr, 48 hr, and 72 hr post-
treatment. GL261 cells treated with 1 mM Rapamycin (Cayman
Chemical) for 24 hr served as positive control, and NT GL261 cells
harvested at the same time points served as negative control. Protein
fractions were collected with use of RIPA Buffer (Sigma-Aldrich).Molecular Therapy: Oncolytics Vol. 5 June 2017 17
Figure 7. Ad/TMZ, but Not TMZ/Ad, Treatment In Vivo Induces Enhanced
Recognition of Glioma Cells by Peripheral T Cells
Splenocytes derived from non-treated (NT), Delta24-RGD (Ad), post-treated (Ad/
TMZ), and pre-treated (TMZ/Ad) mice were cocultured with GL261 cells ex vivo, and
supernatants were assessed for IFN-g in triplicate as a measure of antigen recog-
nition. Splenocytes from virus and post-treated mice, not pre-treated mice, pro-
duced significantly more IFN-g 8 days after viral treatment (pi, black bars, *p < 0.05).
Error bars indicate SD.
Molecular Therapy: OncolyticsBradford Assay (Pierce) was performed to determine protein concen-
trations, and 1,000 mg of protein was loaded onto precast 4%–15%
SDS-PAGE gel (Bio-Rad). The gel was run at 150V for 45 min before
being transferred onto a polyvinylidene ﬂuoride (PVDF) membrane
(Millipore) at 380 mA/85V on ice for 1 hr. The membrane was
washed with Tris-buffered saline-Tween 20 (TBST), blocked for
30 min at room temperature and incubated with primary antibodies
against murine b-actin (1:10,000, Millipore), murine LC3-I/LC3-II
(1:375, Cell Signaling Technology), and murine p62 (1:500, Abcam)
in 0.2% TBST/5% BSA at 4C overnight. After washing, the mem-
brane was incubated with polyclonal anti-rabbit-horseradish peroxi-
dase (HRP) or anti-mouse-HRP (both 1:2,000, DAKO) in 2.5% milk
in TBST for 1 hr at room temperature. After ﬁnal washing, the mem-
brane was incubated with enhanced chemiluminescence (ECL) solu-
tion (Pierce) and scanned using the Chemidoc Imager (Bio-Rad).
Analysis was performed using Image Lab 4.1 software (Bio-Rad).
Detection of Glioma-Reactive Splenocytic T Cells
T cell reactivity in spleens was monitored as described by Pouw
and colleagues.31 In short, splenocytes were pooled per treatment
group and maintained in complete mouse medium containing
RPMI 1640 with 25 mM HEPES and L-glutamine (Life Technolo-
gies) supplemented with 10% FCS, 1% penicillin/streptomycin, 1%
non-essential amino acids (Lonza), 1 mM sodium pyruvate
(Life Technologies), and 50 mM b-mercaptoethanol (Sigma-
Aldrich). The splenocytes were stimulated with concanavalin A
(2.5 mg/mL, Sigma-Aldrich) and 100 U/mL human recombinant
interleukin (IL)-2 (Proleukin, Chiron) for 48 hr. To assess IFN-g
production, 106 stimulated splenocytes were subsequently co-
cultured with 104 GL261 cells for 24 hr. Supernatants were har-
vested, and the level IFN-g was determined with OptEIA ELISA
kit II (BD Biosciences).18 Molecular Therapy: Oncolytics Vol. 5 June 2017Flow Cytometry Analysis of Tumor-Infiltrating Leukocytes
Mice (n = 2 for mono-treatment, n = 3 for combination treatments)
were sacriﬁced, and tumor-containing hemispheres were mechani-
cally dissociated using a 40-mm nylon cell strainer (Corning). Leuko-
cyte fractions from these suspensions were obtained by 30%–70%
Percoll density gradient centrifugation (GE Healthcare Life Sciences)
and stained with CD3, F4/80, and NK1.1 (all eBioscience), CD3, CD4,
CD8, CD11c, CD25, CD45, and I-E[k]/MHCII (all BD Biosciences).
For the intracellular FoxP3 staining, the FoxP3 staining set
(eBioscience) was used according to the manufacturer’s instructions.
Cells were acquired on a FACSAriall (BD Biosciences), and data were
analyzed with Inﬁnicyt software (Cytognos). Prior to gating of
the different cell populations, debris was gated out using FSC-A
and FSC-H parameters. Per staining tube, all time-points were
analyzed together by ﬁle merging and consequent gating.
Statistical Analysis
The students’t test was used for signiﬁcance testing of in vitro exper-
iments. For the survival curve analysis, the log rank test was per-
formed. p values < 0.05 were considered signiﬁcant and are indicated
with asterisks in the graphs. All tests were done using GraphPad
Prism (GraphPad Software).
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